2-chloro-4-morpholine-4-yl-quinazoline-7-carboxylic acid(2-dimethylamino-ethyl)-amide | 1374208-52-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2-chloro-4-morpholine-4-yl-quinazoline-7-carboxylic acid(2-dimethylamino-ethyl)-amide
• 英文别名: 2-Chloro-4-morpholine-4-yl-quinazoline-7-carboxylic acid (2-dimethylamino-ethyl)-amide；2-chloro-N-[2-(dimethylamino)ethyl]-4-morpholin-4-ylquinazoline-7-carboxamide
• CAS: 1374208-52-2
• 化学式: C₁₇H₂₂ClN₅O₂
• 分子量: 363.847
• InChiKey: RZJIWINZVNCIGV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  70.6
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-chloro-4-morpholine-4-yl-quinazoline-7-carboxylic acid(2-dimethylamino-ethyl)-amide 、 N,N-dimethyl-4-{3-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2yl)phenyl]-ureido}-benzamide 在 bis-triphenylphosphine-palladium(II) chloride caesium carbonate 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.33h， 以10%的产率得到2-{4-[3-(4-dimethycarbamoyl-phenyl)-ureido]-phenyl}-4-morpholin-4-yl-quinazoline-7-carboxylic acid(2-dimethylamino-ethyl)-amide
  参考文献：
  名称：

  [EN] SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES
  [FR] DÉRIVÉS DE QUINAZOLINE ET DE PYRIDO-PYRIMIDINE SUBSTITUÉES

  摘要：

  本申请提供了新型的取代喹唑啉和吡啶并嘧啶化合物及其药用盐。还提供了制备这些化合物的方法。通过向患者投与一种或多种化合物的治疗有效量，这些化合物对于通过共同调节PI3K和/或mTOR活性来治疗与PI3K/AKT/mTOR通路失调相关的疾病是有效的。这些化合物具有双重PI3K/mTOR抑制剂的作用。这些化合物可用于治疗多种疾病，包括以炎症或异常细胞增殖为特征的疾病。在一个实施例中，该疾病是癌症。

  公开号：

  WO2012058671A1

文献信息

• Substituted Quinazoline and Pyrido-Pyrimidine Derivatives
  申请人：Smith Roger Astbury

  公开号：US20120129851A1

  公开（公告）日：2012-05-24

  The present application provides novel substituted quinazoline and pyrido-pyrimidine compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in co-regulating PI3K and/or mTOR activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the PI3K/AKT/mTOR pathway. Advantageously, these compounds perform as dual PI3K/mTOR inhibitors. A variety of conditions can be treated using these compounds and include diseases which are characterized by inflammation or abnormal cellular proliferation. In one embodiment, the disease is cancer.

  本申请提供了新型的取代喹唑啉和吡啶并嘧啶化合物及其药学上可接受的盐。同时还提供了制备这些化合物的方法。通过向患者投予一种或多种化合物的治疗有效剂量，这些化合物有助于共同调节PI3K和/或mTOR活性。通过这样做，这些化合物有效地治疗与PI3K/AKT/mTOR通路失调相关的疾病。优点是，这些化合物具有双重PI3K/mTOR抑制剂的作用。这些化合物可以治疗多种疾病，包括以炎症或异常细胞增殖为特征的疾病。在一种实施方式中，该疾病是癌症。
• SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES
  申请人：Asana Biosciences, LLC

  公开号：US20150011547A1

  公开（公告）日：2015-01-08

  The present application provides novel substituted quinazoline and pyrido-pyrimidine compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in co-regulating PI3K and/or mTOR activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the PI3K/AKT/mTOR pathway. Advantageously, these compounds perform as dual PI3K/mTOR inhibitors. A variety of conditions can be treated using these compounds and include diseases which are characterized by inflammation or abnormal cellular proliferation. In one embodiment, the disease is cancer.

  本申请提供了新颖的取代喹唑啉和吡啶并嘧啶化合物及其药学上可接受的盐。还提供了制备这些化合物的方法。通过向患者投予一种或多种化合物的治疗有效量，这些化合物可用于共调节PI3K和/或mTOR活性。通过这样做，这些化合物有效地治疗与PI3K / AKT / mTOR通路失调相关的疾病。有利的是，这些化合物作为双重PI3K / mTOR抑制剂发挥作用。这些化合物可用于治疗各种疾病，包括以炎症或异常细胞增殖为特征的疾病。在一种实施方式中，该疾病是癌症。
• Substituted quinazoline and pyrido-pyrimidine derivatives
  申请人：Smith Roger Astbury

  公开号：US08440662B2

  公开（公告）日：2013-05-14

  The present application provides novel substituted quinazoline and pyrido-pyrimidine compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in co-regulating PI3K and/or mTOR activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the PI3K/AKT/mTOR pathway. Advantageously, these compounds perform as dual PI3K/mTOR inhibitors. A variety of conditions can be treated using these compounds and include diseases which are characterized by inflammation or abnormal cellular proliferation. In one embodiment, the disease is cancer.

  本申请提供了新型的取代喹唑啉和吡啶并嘧啶化合物及其药学上可接受的盐。同时提供了制备这些化合物的方法。通过向患者投予一种或多种化合物的治疗有效量，这些化合物可用于共调节PI3K和/或mTOR活性。通过这样做，这些化合物对治疗与PI3K/AKT/mTOR通路失调相关的疾病具有有效性。有利的是，这些化合物作为双重PI3K/mTOR抑制剂发挥作用。这些化合物可用于治疗各种疾病，包括以炎症或异常细胞增殖为特征的疾病。在一种实施方式中，该疾病是癌症。
• US8440662B2
  申请人：——

  公开号：US8440662B2

  公开（公告）日：2013-05-14
• US9115092B2
  申请人：——

  公开号：US9115092B2

  公开（公告）日：2015-08-25